349 results on '"Lucenteforte E."'
Search Results
2. Inappropriate pharmacological treatment in older adults affected by cardiovascular disease and other chronic comorbidities: a systematic literature review to identify potentially inappropriate prescription indicators
- Author
-
Lucenteforte E, Lombardi N, Vetrano DL, La Carpia D, Mitrova Z, Kirchmayer U, Corrao G, Lapi F, Mugelli A, and Vannacci A
- Subjects
inappropriate prescriptions ,elderly ,cardiovascular diseases ,chronic diseases ,systematic review ,Geriatrics ,RC952-954.6 - Abstract
Ersilia Lucenteforte,1 Niccolò Lombardi,1,* Davide Liborio Vetrano,2,* Domenico La Carpia,2,* Zuzana Mitrova,3 Ursula Kirchmayer,3 Giovanni Corrao,4 Francesco Lapi,5 Alessandro Mugelli,1 Alfredo Vannacci1 On behalf of the Italian Group for Appropriate Drug prescription in the Elderly (I-GrADE) 1Department of Neurosciences, Psychology, Drug Research and Child Health (NEUROFARBA), University of Florence, Florence, Italy; 2Department of Geriatrics Catholic University, Rome, Italy; 3Department of Epidemiology, ASL 1 Rome, Italy; 4Department of Statistics and Quantitative Methods, University of Milano-Bicocca, Milan, Italy; 5Epidemiology Unit, ARS Toscana, Florence, Italy *These authors contributed equally to this work Abstract: Avoiding medications in which the risks outweigh the benefits in the elderly patient is a challenge for physicians, and different criteria to identify inappropriate prescription (IP) exist to aid prescribers. Definition of IP indicators in the Italian geriatric population affected by cardiovascular disease and chronic comorbidities could be extremely useful for prescribers and could offer advantages from a public health perspective. The purpose of the present study was to identify IP indicators by means of a systematic literature review coupled with consensus criteria. A systematic search of PubMed, EMBASE, and CENTRAL databases was conducted, with the search structured around four themes and combining each with the Boolean operator “and”. The first regarded “prescriptions”, the second “adverse events”, the third “cardiovascular conditions”, and the last was planned to identify studies on “older people”. Two investigators independently reviewed titles, abstracts, full texts, and selected articles addressing IP in the elderly affected by cardiovascular condition using the following inclusion criteria: studies on people aged ≥65 years; studies on patients with no restriction on age but with data on subjects aged ≥65 years; and observational effectiveness studies. The database searches produced 5,742 citations. After removing duplicates, titles and abstracts of 3,880 records were reviewed, and 374 full texts were retrieved that met inclusion criteria. Thus, 49 studies reporting 32 potential IP indicators were included in the study. IP indicators regarded mainly drug–drug interactions, cardio- and cerebrovascular risk, bleeding risk, and gastrointestinal risk; among them, only 19 included at least one study that showed significant results, triggering a potential warning for a specific drug or class of drugs in a specific context. This systematic review demonstrates that both cardiovascular and non-cardiovascular drugs increase the risk of adverse drug reactions in older adults with cardiovascular diseases. Keywords: inappropriate prescriptions, elderly, cardiovascular diseases, chronic diseases, systematic review
- Published
- 2017
3. Large-Scale Postmarketing Surveillance of Biological Drugs for Immune-Mediated Inflammatory Diseases Through an Italian Distributed Multi-Database Healthcare Network: The VALORE Project
- Author
-
Trifiro, G., Isgro, V., Ingrasciotta, Y., Ientile, V., L'Abbate, L., Foti, S. S., Belleudi, V., Poggi, F., Fontana, A., Moretti, U., Lora, R., Sabaini, A., Senesi, I., Sorrentino, C., Puzo, M. R., Padula, A., Fusco, M., Giordana, R., Solfrini, V., Puccini, A., Rossi, P., Del Zotto, S., Leoni, O., Zanforlini, M., Ancona, D., Bavaro, V., Garau, D., Ledda, S., Scondotto, S., Allotta, A., Tuccori, M., Gini, R., Bucaneve, G., Franchini, D., Cavazzana, A., Biasi, V., Spila Alegiani, S., Massari, M., Andretta, I., Tanaglia, M., Carriero, A., Sassano, S., De Sarro, G., Mirarchi, S., Palleria, C., Sarro, C., Balestrieri, M., Rostan, S., Capuano, A., Bernardi, F. F., Trama, U., Russo, A., Fumo, M. G., Addis, A., Musicco, F., Sapigni, E., Mazzetti, I., Podetti, D., Potenza, A. M., Nikitina, V., Ricciardelli, R., Mogheiseh, N., Croce, S., Pettinelli, A., Ejlli, L., Fortino, I., Ercolanoni, M., Mazzone, A., Nisic, A., Schiatti, S., Ludergnani, M., Mancini, M., Patregnani, L., Fabbietti, P., Antonicelli, E., Mangano, A., Campomori, A., Urru, S. A., Costa, G., Guarrera, G. M., Stella, P., Serra, E., Carta, P., Vannacci, A., Lucenteforte, E., Parrilli, M., Convertino, I., De Giorgi, M., Rocchi, R. E., Rossi, M., Scroccaro, G., Deambrosis, P., Grindelli, G., Ferroni, E., Trifiro, G., Isgro, V., Ingrasciotta, Y., Ientile, V., L'Abbate, L., Foti, S. S., Belleudi, V., Poggi, F., Fontana, A., Moretti, U., Lora, R., Sabaini, A., Senesi, I., Sorrentino, C., Puzo, M. R., Padula, A., Fusco, M., Giordana, R., Solfrini, V., Puccini, A., Rossi, P., Del Zotto, S., Leoni, O., Zanforlini, M., Ancona, D., Bavaro, V., Garau, D., Ledda, S., Scondotto, S., Allotta, A., Tuccori, M., Gini, R., Bucaneve, G., Franchini, D., Cavazzana, A., Biasi, V., Spila Alegiani, S., Massari, M., Andretta, I., Tanaglia, M., Carriero, A., Sassano, S., De Sarro, G., Mirarchi, S., Palleria, C., Sarro, C., Balestrieri, M., Rostan, S., Capuano, A., Bernardi, F. F., Trama, U., Russo, A., Fumo, M. G., Addis, A., Musicco, F., Sapigni, E., Mazzetti, I., Podetti, D., Potenza, A. M., Nikitina, V., Ricciardelli, R., Mogheiseh, N., Croce, S., Pettinelli, A., Ejlli, L., Fortino, I., Ercolanoni, M., Mazzone, A., Nisic, A., Schiatti, S., Ludergnani, M., Mancini, M., Patregnani, L., Fabbietti, P., Antonicelli, E., Mangano, A., Campomori, A., Urru, S. A., Costa, G., Guarrera, G. M., Stella, P., Serra, E., Carta, P., Vannacci, A., Lucenteforte, E., Parrilli, M., Convertino, I., De Giorgi, M., Rocchi, R. E., Rossi, M., Scroccaro, G., Deambrosis, P., Grindelli, G., and Ferroni, E.
- Subjects
Male ,medicine.medical_specialty ,Population ,Postmarketing surveillance ,Rate ratio ,REGISTRIES ,Retrospective Studie ,Internal medicine ,BIOSIMILARS ,medicine ,Adalimumab ,Humans ,Pharmacology (medical) ,Original Research Article ,education ,Adverse effect ,ANTI-TNF THERAPY, RHEUMATOID-ARTHRITIS, RISK, PHARMACOVIGILANCE, BIOSIMILARS, EXPERIENCE, REGISTRIES, PSORIASIS, MEDICINES, ACCESS ,Biosimilar Pharmaceuticals ,Retrospective Studies ,RISK ,Delivery of Health Care ,Female ,Infliximab ,Italy ,SARS-CoV-2 ,COVID-19 ,Pharmacology ,education.field_of_study ,PSORIASIS ,business.industry ,Biosimilar ,ANTI-TNF THERAPY ,General Medicine ,medicine.disease ,RHEUMATOID-ARTHRITIS ,PHARMACOVIGILANCE ,MEDICINES ,EXPERIENCE ,Immune-mediated inflammatory diseases ,ACCESS ,business ,Human ,Biosimilar Pharmaceutical ,Biotechnology ,medicine.drug - Abstract
Background Biological drugs have improved the management of immune-mediated inflammatory diseases (IMIDs) despite being associated with important safety issues such as immunogenicity, infections, and malignancies in real-world settings. Objective The aim of this study was to explore the potential of a large Italian multi-database distributed network for use in the postmarketing surveillance of biological drugs, including biosimilars, in patients with IMID. Methods A retrospective cohort study was conducted using 13 Italian regional claims databases during 2010–2019. A tailor-made R-based tool developed for distributed analysis of claims data using a study-specific common data model was customized for this study. We measured the yearly prevalence of biological drug users and the frequency of switches between originator and biosimilars for infliximab, etanercept, and adalimumab separately and stratified them by calendar year and region. We then calculated the cumulative number of users and person-years (PYs) of exposure to individual biological drugs approved for IMIDs. For a number of safety outcomes (e.g., severe acute respiratory syndrome coronavirus 2 [SARS-COV-2] infection), we conducted a sample power calculation to estimate the PYs of exposure required to investigate their association with individual biological drugs approved for IMIDs, considering different strengths of association. Results From a total underlying population of almost 50 million inhabitants from 13 Italian regions, we identified 143,602 (0.3%) biological drug users, with a cumulative exposure of 507,745 PYs during the entire follow-up. The mean age ± standard deviation of biological drug users was 49.3 ± 16.3, with a female-to-male ratio of 1.2. The age-adjusted yearly prevalence of biological drug users increased threefold from 0.7 per 1000 in 2010 to 2.1 per 1000 in 2019. Overall, we identified 40,996 users of biosimilars of tumor necrosis factor (TNF)-α inhibitors (i.e., etanercept, adalimumab, and infliximab) in the years 2015–2019. Of these, 46% (N = 18,845) switched at any time between originator and biosimilars or vice versa. To investigate a moderate association (incidence rate ratio 2) between biological drugs approved for IMIDs and safety events of interest, such as optic neuritis (lowest background incidence rate 10.4/100,000 PYs) or severe infection (highest background incidence rate 4312/100,000 PYs), a total of 43,311 PYs and 104 PYs of exposure to individual biological drugs, respectively, would be required. As such, using this network, of 15 individual biological drugs approved for IMIDs, the association with those adverse events could be investigated for four (27%) and 14 (93%), respectively. Conclusion The VALORE project multi-database network has access to data on more than 140,000 biological drug users (and > 0.5 million PYs) from 13 Italian regions during the years 2010–2019, which will be further expanded with the inclusion of data from other regions and more recent calendar years. Overall, the cumulated amount of person-time of exposure to biological drugs approved for IMIDs provides enough statistical power to investigate weak/moderate associations of almost all individual compounds and the most relevant safety outcomes. Moreover, this network may offer the opportunity to investigate the interchangeability of originator and biosimilars of several TNFα inhibitors in different therapeutic areas in real-world settings. Supplementary Information The online version contains supplementary material available at 10.1007/s40259-021-00498-3.
- Published
- 2021
4. Antidepressants and the risk of arrhythmia in elderly affected by a previous cardiovascular disease: a real-life investigation from Italy
- Author
-
Biffi, A., Rea, F., Scotti, L., Mugelli, A., Lucenteforte, E., Bettiol, A., Chinellato, A., Onder, G., Vitale, C., Agabiti, N., Trifirò, G., Roberto, G., Corrao, G., and on behalf of the Italian Group for Appropriate Drug prescription in the Elderly (I-GrADE)
- Published
- 2017
- Full Text
- View/download PDF
5. Diabetes, antidiabetic medications, and pancreatic cancer risk: an analysis from the International Pancreatic Cancer Case-Control Consortium
- Author
-
Bosetti, C., Rosato, V., Li, D., Silverman, D., Petersen, G.M., Bracci, P.M., Neale, R.E., Muscat, J., Anderson, K., Gallinger, S., Olson, S.H., Miller, A.B., Bas Bueno-de-Mesquita, H., Scelo, G., Janout, V., Holcatova, I., Lagiou, P., Serraino, D., Lucenteforte, E., Fabianova, E., Baghurst, P.A., Zatonski, W., Foretova, L., Fontham, E., Bamlet, W.R., Holly, E.A., Negri, E., Hassan, M., Prizment, A., Cotterchio, M., Cleary, S., Kurtz, R.C., Maisonneuve, P., Trichopoulos, D., Polesel, J., Duell, E.J., Boffetta, P., La Vecchia, C., and Ghadirian, P.
- Published
- 2014
- Full Text
- View/download PDF
6. Antidepressants and the Risk of Cardiovascular Events in Elderly Affected by Cardiovascular Disease: A Real-Life Investigation from Italy
- Author
-
Biffi, A, Rea, F, Scotti, L, Lucenteforte, E, Vannacci, A, Lombardi, N, Chinellato, A, Onder, G, Vitale, C, Cascini, S, Ingrasciotta, Y, Roberto, G, Mugelli, A, Corrao, G, Biffi A., Rea F., Scotti L., Lucenteforte E., Vannacci A., Lombardi N., Chinellato A., Onder G., Vitale C., Cascini S., Ingrasciotta Y., Roberto G., Mugelli A., Corrao G., Biffi, A, Rea, F, Scotti, L, Lucenteforte, E, Vannacci, A, Lombardi, N, Chinellato, A, Onder, G, Vitale, C, Cascini, S, Ingrasciotta, Y, Roberto, G, Mugelli, A, Corrao, G, Biffi A., Rea F., Scotti L., Lucenteforte E., Vannacci A., Lombardi N., Chinellato A., Onder G., Vitale C., Cascini S., Ingrasciotta Y., Roberto G., Mugelli A., and Corrao G.
- Abstract
Purpose The purpose of this study was to assess the possible relation between use of antidepressant (AD) drugs, that is, tricyclic ADs, selective serotonin reuptake inhibitors (SSRIs), and atypical ADs (AAs), and the risk of hospitalization for cardiovascular (CV) events among older patients with previous CV diseases. Methods A nested case-control study was carried out among patients aged 65 years and older from 5 Italian health care territorial units who were discharged for CV disease during 2008 to 2010. The cohort was composed by 344,747 individuals, and of these, 97,739 (28%) experienced hospital admission for CV events (myocardial infarction, arrhythmia, stroke, heart failure) during follow-up (until 2014) and were included as cases. Up to 5 controls were randomly selected and matched to each. A conditional logistic regression was fitted to estimate the risk of CV events associated with ADs past or current use. A within-patient comparison was performed by the case-crossover design to account the effect of depression. Findings Current users of SSRIs and AAs were at increased risk of CV events with odds ratios of 1.25 (95% confidence interval, 1.21-1.29) and 1.31 (1.25-1.37), respectively. An increased risk of arrhythmia and stroke was associated with current use of SSRIs and AAs, whereas an increased risk of heart failure was detected with current use of any ADs. The results were confirmed by the case-crossover approach. Implications Evidence that AD use is associated with an increased risk of CV events in accordance with specific mechanisms of action among older people with CV disease was added by this study.
- Published
- 2020
7. Pancreatitis and pancreatic cancer risk: a pooled analysis in the International Pancreatic Cancer Case-Control Consortium (PanC4)
- Author
-
Duell, E.J., Lucenteforte, E., Olson, S.H., Bracci, P.M., Li, D., Risch, H.A., Silverman, D.T., Ji, B.T., Gallinger, S., Holly, E.A., Fontham, E.H., Maisonneuve, P., Bueno-de-Mesquita, H.B., Ghadirian, P., Kurtz, R.C., Ludwig, E., Yu, H., Lowenfels, A.B., Seminara, D., Petersen, G.M., La Vecchia, C., and Boffetta, P.
- Published
- 2012
- Full Text
- View/download PDF
8. Cigarette smoking and pancreatic cancer: an analysis from the International Pancreatic Cancer Case-Control Consortium (Panc4)
- Author
-
Bosetti, C., Lucenteforte, E., Silverman, D.T., Petersen, G., Bracci, P.M., Ji, B.T., Negri, E., Li, D., Risch, H.A., Olson, S.H., Gallinger, S., Miller, A.B., Bueno-de-Mesquita, H.B., Talamini, R., Polesel, J., Ghadirian, P., Baghurst, P.A., Zatonski, W., Fontham, E., Bamlet, W.R., Holly, E.A., Bertuccio, P., Gao, Y.T., Hassan, M., Yu, H., Kurtz, R.C., Cotterchio, M., Su, J., Maisonneuve, P., Duell, E.J., Boffetta, P., and La Vecchia, C.
- Published
- 2012
- Full Text
- View/download PDF
9. All-cause mortality and antipsychotic use among elderly persons with high baseline cardiovascular and cerebrovascular risk: a multi-center retrospective cohort study in Italy
- Author
-
Sultana J., Giorgianni F., REA, FEDERICO, Lucenteforte E., Lombardi N., Mugelli A., Vannacci A., Liperoti R., Kirchmayer U., Vitale C., Chinellato A., Roberto G., Corrao G., Trifiro G., Agabiti N., Bartolini C., Bernabei R., Bettiol A., Bonassi S., Caputi A. P., Cascini S., Cipriani F., Davoli M., Fini M., Gini R., Lapi F., Onder G., Sorge C., Tari M., Vetrano D. L., Sultana, J, Giorgianni, F, Rea, F, Lucenteforte, E, Lombardi, N, Mugelli, A, Vannacci, A, Liperoti, R, Kirchmayer, U, Vitale, C, Chinellato, A, Roberto, G, Corrao, G, Trifiro, G, Agabiti, N, Bartolini, C, Bernabei, R, Bettiol, A, Bonassi, S, Caputi, A, Cascini, S, Cipriani, F, Davoli, M, Fini, M, Gini, R, Lapi, F, Onder, G, Sorge, C, Tari, M, and Vetrano, D
- Subjects
Male ,Pediatrics ,medicine.medical_treatment ,Toxicology ,030226 pharmacology & pharmacy ,Cohort Studies ,Antipsychotic ,0302 clinical medicine ,Retrospective Studie ,Risk Factors ,Cardiovascular Disease ,80 and over ,Antipsychotics ,Medicine ,Drug Interactions ,Aged, 80 and over ,Incidence ,Incidence (epidemiology) ,General Medicine ,Italy ,Cardiovascular Diseases ,030220 oncology & carcinogenesis ,Cerebrovascular Disorder ,Female ,cohort study ,drug interactions ,elderly ,mortality ,Antipsychotic Agents ,Human ,Cohort study ,medicine.medical_specialty ,03 medical and health sciences ,Elderly persons ,Humans ,Cerebrovascular risk ,Proportional Hazards Models ,Retrospective Studies ,Aged ,Pharmacology ,drug interaction ,urogenital system ,business.industry ,Proportional hazards model ,Settore MED/09 - MEDICINA INTERNA ,Retrospective cohort study ,equipment and supplies ,Cerebrovascular Disorders ,Antipsychotic Agent ,Proportional Hazards Model ,Cohort Studie ,business ,All cause mortality - Abstract
Background: Little is known about the comparative risk of death with atypical or conventional antipsychotics (APs) among persons with cardiovascular or cerebrovascular disease (CCD). Research design and methods: A cohort study was conducted using five Italian claims databases. New atypical AP users with CCD aged ≥65 (reference) were matched to new conventional AP users. Mortality per 100 person-years (PYs) and hazard ratios (HR), estimated using Cox models, were reported. Incidence and risk of death were estimated for persons having drug–drug interactions. Outcome occurrence was evaluated 180 days after AP initiation. Results: Overall 24,711 and 27,051 elderly new conventional and atypical AP users were identified. The mortality rate was 51.3 and 38.5 deaths per 100 PYs for conventional and atypical AP users. Mortality risk was 1.33 (95%CI: 1.27–1.39) for conventional APs. There was no increased mortality risk with single drug–drug interactions (DDIs) vs. no DDI. AP users with ≥1 DDI had a 29% higher mortality risk compared to no DDI in the first 90 days of treatment (HR: 1.29 (95% CI: 1.00–1.67)). Conclusions: Conventional APs had a higher risk of death than atypical APs among elderly persons with CCD. Having ≥1 DDI was associated with an increased risk of death.
- Published
- 2019
10. Cigar and pipe smoking, smokeless tobacco use and pancreatic cancer: an analysis from the International Pancreatic Cancer Case-Control Consortium (PanC4)
- Author
-
Bertuccio, P., La Vecchia, C., Silverman, D.T., Petersen, G.M., Bracci, P.M., Negri, E., Li, D., Risch, H.A., Olson, S.H., Gallinger, S., Miller, A.B., Bueno-de-Mesquita, H.B., Talamini, R., Polesel, J., Ghadirian, P., Baghurst, P.A., Zatonski, W., Fontham, E.T., Bamlet, W.R., Holly, E.A., Lucenteforte, E., Hassan, M., Yu, H., Kurtz, R.C., Cotterchio, M., Su, J., Maisonneuve, P., Duell, E.J., Bosetti, C., and Boffetta, P.
- Published
- 2011
- Full Text
- View/download PDF
11. Management of psychogenic non-epileptic seizures: a multidisciplinary approach
- Author
-
Gasparini, S, Beghi, E, Ferlazzo, E, Beghi, M, Belcastro, V, Biermann, K, Bottini, G, Capovilla, G, Cervellione, R, Cianci, V, Coppola, G, Cornaggia, C, De Fazio, P, De Masi, S, De Sarro, G, Elia, M, Erba, G, Fusco, L, Gambardella, A, Gentile, V, Giallonardo, A, Guerrini, R, Ingravallo, F, Iudice, A, Labate, A, Lucenteforte, E, Magaudda, A, Mumoli, L, Papagno, C, Pesce, G, Pucci, E, Ricci, P, Romeo, A, Quintas, R, Sueri, C, Vitaliti, G, Zoia, R, Aguglia, U, Gasparini S., Beghi E., Ferlazzo E., Beghi M., Belcastro V., Biermann K. P., Bottini G., Capovilla G., Cervellione R. A., Cianci V., Coppola G., Cornaggia C. M., De Fazio P., De Masi S., De Sarro G., Elia M., Erba G., Fusco L., Gambardella A., Gentile V., Giallonardo A. T., Guerrini R., Ingravallo F., Iudice A., Labate A., Lucenteforte E., Magaudda A., Mumoli L., Papagno C., Pesce G. B., Pucci E., Ricci P., Romeo A., Quintas R., Sueri C., Vitaliti G., Zoia R., Aguglia U., Gasparini, S, Beghi, E, Ferlazzo, E, Beghi, M, Belcastro, V, Biermann, K, Bottini, G, Capovilla, G, Cervellione, R, Cianci, V, Coppola, G, Cornaggia, C, De Fazio, P, De Masi, S, De Sarro, G, Elia, M, Erba, G, Fusco, L, Gambardella, A, Gentile, V, Giallonardo, A, Guerrini, R, Ingravallo, F, Iudice, A, Labate, A, Lucenteforte, E, Magaudda, A, Mumoli, L, Papagno, C, Pesce, G, Pucci, E, Ricci, P, Romeo, A, Quintas, R, Sueri, C, Vitaliti, G, Zoia, R, Aguglia, U, Gasparini S., Beghi E., Ferlazzo E., Beghi M., Belcastro V., Biermann K. P., Bottini G., Capovilla G., Cervellione R. A., Cianci V., Coppola G., Cornaggia C. M., De Fazio P., De Masi S., De Sarro G., Elia M., Erba G., Fusco L., Gambardella A., Gentile V., Giallonardo A. T., Guerrini R., Ingravallo F., Iudice A., Labate A., Lucenteforte E., Magaudda A., Mumoli L., Papagno C., Pesce G. B., Pucci E., Ricci P., Romeo A., Quintas R., Sueri C., Vitaliti G., Zoia R., and Aguglia U.
- Abstract
The International League against Epilepsy (ILAE) proposed a diagnostic scheme for psychogenic non-epileptic seizure (PNES). The debate on ethical aspects of the diagnostic procedures is ongoing, the treatment is not standardized and management might differ according to age group. The objective was to reach an expert and stakeholder consensus on PNES management. A board comprising adult and child neurologists, neuropsychologists, psychiatrists, pharmacologists, experts in forensic medicine and bioethics as well as patients’ representatives was formed. The board chose five main topics regarding PNES: diagnosis; ethical issues; psychiatric comorbidities; psychological treatment; and pharmacological treatment. After a systematic review of the literature, the board met in a consensus conference in Catanzaro (Italy). Further consultations using a model of Delphi panel were held. The global level of evidence for all topics was low. Even though most questions were formulated separately for children/adolescents and adults, no major age-related differences emerged. The board established that the approach to PNES diagnosis should comply with ILAE recommendations. Seizure induction was considered ethical, preferring the least invasive techniques. The board recommended looking carefully for mood disturbances, personality disorders and psychic trauma in persons with PNES and considering cognitive-behavioural therapy as a first-line psychological approach and pharmacological treatment to manage comorbid conditions, namely anxiety and depression. Psychogenic non-epileptic seizure management should be multidisciplinary. High-quality long-term studies are needed to standardize PNES management.
- Published
- 2019
12. A Systematic Review of Case-Identification Algorithms for 18 Conditions Based on Italian Healthcare Administrative Databases: A Study Protocol
- Author
-
Canova, C, Simonato, L, Barbiellini Amidei, C, Baldi, I, Dalla Zuanna, T, Gregori, D, Danieli, S, Buja, A, Lorenzoni, G, Pitter, G, Costa, G, Gnavi, R, Corrao, G, Rea, F, Gini, R, Hyeraci, G, Roberto, G, Spini, A, Lucenteforte, E, Agabiti, N, Davoli, M, Di Domenicantonio, R, Cappai, G, Canova C., Simonato L., Barbiellini Amidei C., Baldi I., Dalla Zuanna T., Gregori D., Danieli S., Buja A., Lorenzoni G., Pitter G., Costa G., Gnavi R., Corrao G., Rea F., Gini R., Hyeraci G., Roberto G., Spini A., Lucenteforte E., Agabiti N., Davoli M., Di Domenicantonio R., Cappai G., Canova, C, Simonato, L, Barbiellini Amidei, C, Baldi, I, Dalla Zuanna, T, Gregori, D, Danieli, S, Buja, A, Lorenzoni, G, Pitter, G, Costa, G, Gnavi, R, Corrao, G, Rea, F, Gini, R, Hyeraci, G, Roberto, G, Spini, A, Lucenteforte, E, Agabiti, N, Davoli, M, Di Domenicantonio, R, Cappai, G, Canova C., Simonato L., Barbiellini Amidei C., Baldi I., Dalla Zuanna T., Gregori D., Danieli S., Buja A., Lorenzoni G., Pitter G., Costa G., Gnavi R., Corrao G., Rea F., Gini R., Hyeraci G., Roberto G., Spini A., Lucenteforte E., Agabiti N., Davoli M., Di Domenicantonio R., and Cappai G.
- Abstract
BACKGROUND: there has been a long-standing, consistent use worldwide of Healthcare Administrative Databases (HADs) for epidemiological purposes, especially to identify acute and chronic health conditions. These databases are able to reflect health-related conditions at a population level through disease-specific case-identification algorithms that combine information coded in multiple HADs. In Italy, in the past 10 years, HAD-based case-identification algorithms have experienced a constant increase, with a significant extension of the spectrum of identifiable diseases. Besides estimating incidence and/or prevalence of diseases, these algorithms have been used to enroll cohorts, monitor quality of care, assess the effect of environmental exposure, and identify health outcomes in analytic studies. Despite the rapid increase in the use of case-identification algorithms, information on their accuracy and misclassification rate is currently unavailable for most conditions. OBJECTIVES: to define a protocol to systematically review algorithms used in Italy in the past 10 years for the identification of several chronic and acute diseases, providing an accessible overview to future users in the Italian and international context. METHODS: PubMed will be searched for original research articles, published between 2007 and 2017, in Italian or English. The search string consists of a combination of free text and MeSH terms with a common part on HADs and a disease-specific part. All identified papers will be screened for eligibility by two independent reviewers. All articles that used/defined an algorithm for the identification of each disease of interest using Italian HADs will be included. Algorithms with exclusive use of death certificates, pathology register, general practitioner or pediatrician data will be excluded. Pertinent papers will be classified according to the objective for which the algorithm was used, and only articles that used algorithms with "primary objectives"
- Published
- 2019
13. All-cause mortality and antipsychotic use among elderly persons with high baseline cardiovascular and cerebrovascular risk: a multi-center retrospective cohort study in Italy
- Author
-
Sultana, J, Giorgianni, F, Rea, F, Lucenteforte, E, Lombardi, N, Mugelli, A, Vannacci, A, Liperoti, R, Kirchmayer, U, Vitale, C, Chinellato, A, Roberto, G, Corrao, G, Trifiro, G, Agabiti, N, Bartolini, C, Bernabei, R, Bettiol, A, Bonassi, S, Caputi, A, Cascini, S, Cipriani, F, Davoli, M, Fini, M, Gini, R, Lapi, F, Onder, G, Sorge, C, Tari, M, Vetrano, D, Sultana J., Giorgianni F., REA, FEDERICO, Lucenteforte E., Lombardi N., Mugelli A., Vannacci A., Liperoti R., Kirchmayer U., Vitale C., Chinellato A., Roberto G., Corrao G., Trifiro G., Agabiti N., Bartolini C., Bernabei R., Bettiol A., Bonassi S., Caputi A. P., Cascini S., Cipriani F., Davoli M., Fini M., Gini R., Lapi F., Onder G., Sorge C., Tari M., Vetrano D. L., Sultana, J, Giorgianni, F, Rea, F, Lucenteforte, E, Lombardi, N, Mugelli, A, Vannacci, A, Liperoti, R, Kirchmayer, U, Vitale, C, Chinellato, A, Roberto, G, Corrao, G, Trifiro, G, Agabiti, N, Bartolini, C, Bernabei, R, Bettiol, A, Bonassi, S, Caputi, A, Cascini, S, Cipriani, F, Davoli, M, Fini, M, Gini, R, Lapi, F, Onder, G, Sorge, C, Tari, M, Vetrano, D, Sultana J., Giorgianni F., REA, FEDERICO, Lucenteforte E., Lombardi N., Mugelli A., Vannacci A., Liperoti R., Kirchmayer U., Vitale C., Chinellato A., Roberto G., Corrao G., Trifiro G., Agabiti N., Bartolini C., Bernabei R., Bettiol A., Bonassi S., Caputi A. P., Cascini S., Cipriani F., Davoli M., Fini M., Gini R., Lapi F., Onder G., Sorge C., Tari M., and Vetrano D. L.
- Abstract
Background: Little is known about the comparative risk of death with atypical or conventional antipsychotics (APs) among persons with cardiovascular or cerebrovascular disease (CCD). Research design and methods: A cohort study was conducted using five Italian claims databases. New atypical AP users with CCD aged ≥65 (reference) were matched to new conventional AP users. Mortality per 100 person-years (PYs) and hazard ratios (HR), estimated using Cox models, were reported. Incidence and risk of death were estimated for persons having drug–drug interactions. Outcome occurrence was evaluated 180 days after AP initiation. Results: Overall 24,711 and 27,051 elderly new conventional and atypical AP users were identified. The mortality rate was 51.3 and 38.5 deaths per 100 PYs for conventional and atypical AP users. Mortality risk was 1.33 (95%CI: 1.27–1.39) for conventional APs. There was no increased mortality risk with single drug–drug interactions (DDIs) vs. no DDI. AP users with ≥1 DDI had a 29% higher mortality risk compared to no DDI in the first 90 days of treatment (HR: 1.29 (95% CI: 1.00–1.67)). Conclusions: Conventional APs had a higher risk of death than atypical APs among elderly persons with CCD. Having ≥1 DDI was associated with an increased risk of death.
- Published
- 2019
14. The development of a Consensus Conference on Pediatric Procedural Sedation in the Emergency Department in Italy: From here where to?
- Author
-
Sforzi I., Bressan S., Saffirio C., De Masi S., Bussolin L., Da Dalt L., De Iaco F., Shavit I., Krauss B., Barbi E., Bergese I., Biermann K. P., Borrometi F., Calligaris L., Cantoni B., Fontanazza S., Fornasari D., Ghizzi C., Gregorini M., Guarino M., L'erario M., La Fauci G., Lai A., Lazzeri S., Leo M. C., Lucenteforte E., Macchiarini A., Maiandi S., Mando M., Mazza A., Montobbio G., Mugelli A., Parrino R., Sammartino M., Schleef J., Spotti A., Tomasello C., Di Francia M. T., Trapani C., Turini M., Vagnoli L., Vergna S., Virgili G., Rosati G. V., Zanon D., Sforzi, I., Bressan, S., Saffirio, C., De Masi, S., Bussolin, L., Da Dalt, L., De Iaco, F., Shavit, I., Krauss, B., Barbi, E., Bergese, I., Biermann, K. P., Borrometi, F., Calligaris, L., Cantoni, B., Fontanazza, S., Fornasari, D., Ghizzi, C., Gregorini, M., Guarino, M., L'Erario, M., La Fauci, G., Lai, A., Lazzeri, S., Leo, M. C., Lucenteforte, E., Macchiarini, A., Maiandi, S., Mando, M., Mazza, A., Montobbio, G., Mugelli, A., Parrino, R., Sammartino, M., Schleef, J., Spotti, A., Tomasello, C., Di Francia, M. T., Trapani, C., Turini, M., Vagnoli, L., Vergna, S., Virgili, G., Rosati, G. V., and Zanon, D.
- Subjects
Consensus ,medicine.medical_treatment ,Training system ,MEDLINE ,Conscious Sedation ,Consensu ,Subspecialty ,Pediatrics ,Emergency department ,Pediatric ,Procedural sedation and analgesia ,03 medical and health sciences ,Hospital ,0302 clinical medicine ,Pediatric emergency medicine ,030202 anesthesiology ,Multidisciplinary approach ,030225 pediatrics ,Health care ,Medicine ,Humans ,Emergency Service ,business.industry ,Research ,lcsh:RJ1-570 ,lcsh:Pediatrics ,medicine.disease ,Italy ,Emergency Medicine ,Analgesia ,Emergency Service, Hospital ,Medical emergency ,business ,Human - Abstract
Background In Italy, as in many European countries, Pediatric Emergency Medicine is not formally recognized as a pediatric subspecialty, hindering nation-wide adoption of standards of care, especially in the field of procedural sedation and analgesia (PSA) in the Emergency Department (ED). For this reason PSA in Italy is mostly neglected or performed very heterogeneously and by different providers, with no reference standard. We aimed to describe the procedures and results of the first multidisciplinary and multi-professional Consensus Conference in Italy on safe and effective pediatric PSA in Italian EDs. Methods The preparation, organization and conduct of the Consensus Conference, held in Florence in 2017, followed the recommended National methodological standards. Professionals from different specialties across the country were invited to participate. Results Overall 86 recommendations covering 8 themes (pre-sedation evaluation, pharmacologic agents, monitoring, equipment and discharge checklists, training, non-pharmacologic techniques, the adult ED setting, impact on hospitalizations) were developed, taking into account the Italian training system and healthcare organization characteristics. Conclusion The results of the first multidisciplinary and multi-professional Consensus Conference in Italy are meant to provide up-to-date national guidance to improve the standard of care of children undergoing painful and stressful procedures in the ED. The recommendations will be periodically updated as new relevant evidence is published.
- Published
- 2020
15. AF.64 TRAJECTORIES OF ORAL BUDESONIDE USE IN CROHN’S DISEASE COHORT OF TUSCAN PATIENTS
- Author
-
Bertani, L., primary, Ferraro, S., additional, Bartolini, C., additional, Convertino, I., additional, Giometto, S., additional, Cappello, E., additional, Valdiserra, G., additional, Tillati, S., additional, Blandizzi, C., additional, Lucenteforte, E., additional, Gini, R., additional, Tuccori, M., additional, and Costa, F., additional
- Published
- 2021
- Full Text
- View/download PDF
16. AF.55 ADHERENCE TO MESALAZINE AND IDENTIFICATION OF PATIENTS WITH ULCERATIVE COLITIS IN HEALTHCARE ADMINISTRATIVE DATABASES OF TUSCANY (ITALY)
- Author
-
Bertani, L., primary, Bartolini, C., additional, Ferraro, S., additional, Convertino, I., additional, Giometto, S., additional, Tillati, S., additional, Valdiserra, G., additional, Cappello, E., additional, Blandizzi, C., additional, Lucenteforte, E., additional, Gini, R., additional, Tuccori, M., additional, and Costa, F., additional
- Published
- 2021
- Full Text
- View/download PDF
17. AF.58 DIAGNOSTIC DELAY, EFFECTIVENESS AND SAFETY OUTCOMES IN A REAL-WORLD COHORT OF PATIENTS WITH CROHN’S DISEASE: DATA FROM ADMINISTRATIVE DATABASES IN TUSCANY, ITALY
- Author
-
Bertani, L., primary, Ferraro, S., additional, Bartolini, C., additional, Convertino, I., additional, Giometto, S., additional, Cappello, E., additional, Valdiserra, G., additional, Tillati, S., additional, Blandizzi, C., additional, Lucenteforte, E., additional, Gini, R., additional, Tuccori, M., additional, and Costa, F., additional
- Published
- 2021
- Full Text
- View/download PDF
18. Macronutrients, fatty acids and cholesterol intake and stomach cancer risk
- Author
-
Lucenteforte, E., Bosetti, C., Gallus, S., Bertuccio, P., Pelucchi, C., Tavani, A., La Vecchia, C., and Negri, E.
- Published
- 2009
- Full Text
- View/download PDF
19. P651 Diagnostic delay, effectiveness and safety outcomes in a real-world cohort of patients with Crohn’s disease: data from administrative databases in Tuscany, Italy
- Author
-
Bertani, L, primary, Ferraro, S, additional, Bartolini, C, additional, Convertino, I, additional, Giometto, S, additional, Cappello, E, additional, Valdiserra, G, additional, Tillati, S, additional, Blandizzi, C, additional, Lucenteforte, E, additional, Gini, R, additional, Tuccori, M, additional, and Costa, F, additional
- Published
- 2021
- Full Text
- View/download PDF
20. P634 Trajectories of oral budesonide use in Crohn’s disease cohort of Tuscan patients
- Author
-
Bertani, L, primary, Ferraro, S, additional, Bartolini, C, additional, Convertino, I, additional, Giometto, S, additional, Cappello, E, additional, Valdiserra, G, additional, Tillati, S, additional, Blandizzi, C, additional, Lucenteforte, E, additional, Gini, R, additional, Tuccori, M, additional, and Costa, F, additional
- Published
- 2021
- Full Text
- View/download PDF
21. P664 Adherence to mesalazine and identification of patients with ulcerative colitis in healthcare administrative databases of Tuscany (Italy)
- Author
-
Bertani, L, primary, Bartolini, C, additional, Ferraro, S, additional, Convertino, I, additional, Giometto, S, additional, Tillati, S, additional, Valdiserra, G, additional, Cappello, E, additional, Blandizzi, C, additional, Lucenteforte, E, additional, Gini, R, additional, Tuccori, M, additional, and Costa, F, additional
- Published
- 2021
- Full Text
- View/download PDF
22. The management of pediatric severe traumatic brain injury: Italian guidelines
- Author
-
Bussolin, L., Falconi, M., Leo, M. C., Parri, N., De Masi, Salvatore, Rosati, A., Cecchi, C., Spacca, B., Grandoni, M., Bettiol, A., Lucenteforte, E., Lubrano, R., Falsaperla, R., Melosi, F., Agostiniani, R., Mangiantini, F., Talamonti, G., Calderini, E., Mancino, Aldo, De Luca, Marianna, Conti, Giorgio, Petrini, F., Angileri, S., Baldazzi, M., Bertuetti, R., Biermann, K. P., Bigagli, E., Carai, A., Coniglio, C., Conio, A., Crescioli, M., D'Amato, L., Grassi, A., Iaccarino, C., Macchiarini, A., Magnoni, S., Masotti, A., Meneghini, L., Minardi, C., Moscatelli, A., Pedretti, Marisa, Piazza, S., Picardo, S. G., Pittalis, A., Pizzi, S., Pompucci, Angelo, Pugi, A., Rizzo, G., Sagredini, R., Silipo, R., Stoppa, F., and Tuccinardi, G.
- Subjects
Adult ,medicine.medical_specialty ,Traumatic brain injury ,MEDLINE ,Guideline ,Brain injuries ,Pediatrics ,Brain injuries, traumatic ,Glasgow coma scale ,Child ,Humans ,Italy ,Brain Injuries, Traumatic ,Language ,03 medical and health sciences ,0302 clinical medicine ,traumatic ,030202 anesthesiology ,Multidisciplinary approach ,Medicine ,Guideline development ,business.industry ,030208 emergency & critical care medicine ,medicine.disease ,Quality of evidence ,Anesthesiology and Pain Medicine ,Settore MED/38 - PEDIATRIA GENERALE E SPECIALISTICA ,Family medicine ,business ,Inclusion (education) ,Evidence synthesis - Abstract
Introduction The aim of the work was to update the "Guidelines for the Management of Severe Traumatic Brain Injury" published in 2012, to reflect the new available evidence, and develop the Italian national guideline for the management of severe pediatric head injuries to reduce variation in practice and ensure optimal care to patients. Evidence acquisition MEDLINE and EMBASE were searched from January 2009 to October 2017. Inclusion criteria were English language, pediatric populations (0-18 years) or mixed populations (pediatric/adult) with available age subgroup analyses. The guideline development process was started by the Promoting Group that composed a multidisciplinary panel of experts, with the representatives of the Scientific Societies, the independent expert specialists and a representative of the Patient Associations. The panel selected the clinical questions, discussed the evidence and formulated the text of the recommendations. The documentarists of the University of Florence oversaw the bibliographic research strategy. A group of literature reviewers evaluated the selected literature and compiled the table of evidence for each clinical question. Evidence synthesis The search strategies identified 4254 articles. We selected 3227 abstract (first screening) and, finally included 67 articles (second screening) to update the guideline. This Italian update includes 25 evidence-based recommendations and 5 research recommendations. Conclusions In recent years, progress has been made on the understanding of severe pediatric brain injury, as well as on that concerning all major traumatic pathology. This has led to a progressive improvement in the clinical outcome, although the quantity and quality of evidence remains particularly low.
- Published
- 2021
23. Artificial intelligence for detecting keratoconus
- Author
-
Vandevenne, Magali, Favuzza, Eleonora, Veta, Mitko, Lucenteforte, E., Berendschot, Tos, Mencucci, Rita, Nuijts, Rudy, Virgil, Gianni, Dickman, Mor M., Vandevenne, Magali, Favuzza, Eleonora, Veta, Mitko, Lucenteforte, E., Berendschot, Tos, Mencucci, Rita, Nuijts, Rudy, Virgil, Gianni, and Dickman, Mor M.
- Abstract
Objectives: This is a protocol for a Cochrane Review (diagnostic). The objectives are as follows:. The primary objective is to assess the diagnostic accuracy of AI algorithms in the detection of keratoconus in patients presenting with refractive errors, especially those whose vision can no longer be corrected fully with glasses, patients seeking corneal refractive surgery or those suspected of having keratoconus. AI could help ophthalmologists, optometrists and other eye-care professionals to make decisions on referral to cornea specialists for these patients. Secondary objectives To compare different AI algorithms, e.g. neural networks, decision trees, support vector machines. To assess potential causes of heterogeneity in diagnostic performance across studies, according to the following: index test methodology: pre-processing techniques, core AI method and postprocessing techniques; sources of input to train algorithms: topography and tomography images from Placido-disc system or Scheimpflug system or slit-scanning system or OCT, number of training and testing cases/images, label/endpoint variable used for training; study setting; study design, retrospective or prospective studies; ethnicity, or geographic area as its proxy; different index test positivity criteria provided by topography or tomography device; reference standard used, topography or tomography, one or two cornea-specialists; definition of keratoconus used; mean age; patient recruitment; severity of keratoconus: clinically manifest keratoconus subclinical keratoconus.
- Published
- 2021
24. Macronutrients, fatty acids and cholesterol intake and endometrial cancer
- Author
-
Lucenteforte, E., Talamini, R., Montella, M., Dal Maso, L., Tavani, A., Deandrea, S., Pelucchi, C., Greggi, S., Zucchetto, A., Barbone, F., Parpinel, M., Franceschi, S., La Vecchia, C., and Negri, E.
- Published
- 2008
- Full Text
- View/download PDF
25. Potential drug–drug interactions and radiodiagnostic procedures: an in-hospital survey
- Author
-
Lapi, F., Vietri, M., Moschini, M., Cecchi, E., Pugi, A., Lucenteforte, E., Banchelli, G., Di Pirro, M., Gallo, E., Mugelli, A., and Vannacci, A.
- Published
- 2010
- Full Text
- View/download PDF
26. The Role of European Healthcare Databases for Post-Marketing Drug Effectiveness, Safety and Value Evaluation: Where Does Italy Stand?
- Author
-
Trifirò, G, Gini, R, Barone-Adesi, F, Beghi, E, Cantarutti, A, Capuano, A, Carnovale, C, Clavenna, A, Dellagiovanna, M, Ferrajolo, C, Franchi, M, Ingrasciotta, Y, Kirchmayer, U, Lapi, F, Leone, R, Leoni, O, Lucenteforte, E, Moretti, U, Mugelli, A, Naldi, L, Poluzzi, E, Rafaniello, C, Rea, F, Sultana, J, Tettamanti, M, Traversa, G20, Vannacci, A, Mantovani, L, Corrao, G, Trifirò, Gianluca, Trifiro G., Gini R., Barone-Adesi F., Beghi E., Cantarutti A., Capuano A., Carnovale C., Clavenna A., Dellagiovanna M., Ferrajolo C., Franchi M., Ingrasciotta Y., Kirchmayer U., Lapi F., Leone R., Leoni O., Lucenteforte E., Moretti U., Mugelli A., Naldi L., Poluzzi E., Rafaniello C., Rea F., Sultana J., Tettamanti M., Traversa G., Vannacci A., Mantovani L., Corrao G., Trifirò, Gianluca, Gini, Rosa, Barone-Adesi, Francesco, Beghi, Ettore, Cantarutti, Anna, Capuano, Annalisa, Carnovale, Carla, Clavenna, Antonio, Dellagiovanna, Mirosa, Ferrajolo, Carmen, Franchi, Matteo, Ingrasciotta, Ylenia, Kirchmayer, Ursula, Lapi, Francesco, Leone, Roberto, Leoni, Olivia, Lucenteforte, Ersilia, Moretti, Ugo, Mugelli, Alessandro, Naldi, Luigi, Poluzzi, Elisabetta, Rafaniello, Concita, Rea, Federico, Sultana, Janet, Tettamanti, Mauro, Traversa, Giuseppe, Vannacci, Alfredo, Mantovani, Lorenzo, Corrao, Giovanni, Trifirò, G, Gini, R, Barone-Adesi, F, Beghi, E, Cantarutti, A, Capuano, A, Carnovale, C, Clavenna, A, Dellagiovanna, M, Ferrajolo, C, Franchi, M, Ingrasciotta, Y, Kirchmayer, U, Lapi, F, Leone, R, Leoni, O, Lucenteforte, E, Moretti, U, Mugelli, A, Naldi, L, Poluzzi, E, Rafaniello, C, Rea, F, Sultana, J, Tettamanti, M, Traversa, G, Vannacci, A, Mantovani, L, and Corrao, G
- Subjects
Drug ,Value (ethics) ,Pharmacovigilance, Drug Toxicity, spontaneous reporting ,Databases, Factual ,Drug-Related Side Effects and Adverse Reactions ,National Health Programs ,media_common.quotation_subject ,National Health Program ,MEDLINE ,spontaneous reporting ,Information Storage and Retrieval ,Disease ,Toxicology ,computer.software_genre ,030226 pharmacology & pharmacy ,Pharmacovigilance ,03 medical and health sciences ,Pharmacology ,Pharmacology (medical) ,0302 clinical medicine ,Drug Utilization Review ,Drug Toxicity ,Health care ,Product Surveillance, Postmarketing ,Medicine ,Electronic Health Records ,030212 general & internal medicine ,media_common ,Database ,business.industry ,Health technology ,Italy ,Observational study ,Electronic Health Record ,business ,Drug-Related Side Effects and Adverse Reaction ,computer - Abstract
Enormous progress has been made globally in the use of evidence derived from patients’ clinical information as they access their routine medical care. The value of real-world data lies in their complementary nature compared with data from randomised controlled trials: less detailed information on drug efficacy but longer observational periods and larger, more heterogeneous study populations reflecting clinical practice because individuals are included who would not usually be recruited in trials. Real-world data can be collected in various types of electronic sources, such as electronic health records, claims databases and drug or disease registries. These data sources vary in nature from country to country, according to national healthcare system structures and national policies. In Italy, a growing number of healthcare databases have been used to evaluate post-marketing drug utilisation and safety in the last two decades. The aim of this narrative review is to describe the available Italian sources of real-world data and their contribution to generating post-marketing evidence on drug use and safety. We also discuss the strengths and limitations of the most commonly used Italian healthcare databases in addressing various research questions concerning drug utilisation, comparative effectiveness and safety studies, as well as health technology assessment and other areas.
- Published
- 2018
27. A systematic review of case-identification algorithms based on italian healthcare administrative databases for three relevant diseases of the cardiovascular system: Acute myocardial infarction, ischemic heart disease, and stroke
- Author
-
Hyeraci, G., Spini, A., Roberto, G., Gini, R., Bartolini, C., Lucenteforte, E., Corrao, G., Rea, F., Hyeraci, G, Spini, A, Roberto, G, Gini, R, Bartolini, C, Lucenteforte, E, Corrao, G, and Rea, F
- Subjects
Databases, Factual ,Healthcare administrative databases ,Ischemic heart disease ,Myocardial Infarction ,Myocardial Ischemia ,Ischemic Hearth DIsease ,Algorithm ,Stroke ,Italy ,Healthcare administrative database ,Ischemic heart diseases ,Acute Myocardial Infarction ,Humans ,Acute myocardial infarction ,Algorithms ,Health Services Administration - Abstract
BACKGROUND: acute myocardial infarction (AMI), ischemic heart diseases (IHDs) and stroke are serious cardiovascular diseases (CVDs) which may lead to hospitalizations, require periodical medical monitoring and life-long drugs use, thus having a high impact on public health and Healthcare Service expenditure. In this contest, Italian Healthcare Administrative Databases (HADs), which routinely collect patient-level information on healthcare services reimbursed by the National Healthcare service, are increasingly used for identification of these CVDs. ObjectiveS: to identify and describe all AMI, IHDs and stroke case-identification algorithms by means of Italian HADs, through the review of papers published in the past 10 years. Methods: this study is part of a project that systematically reviewed case-identification algorithms for 18 acute and chronic conditions by means of HADs in Italy. PubMed was searched for original articles, published between 2007 and 2017, in Italian or English. The search string consisted of a combination of free text and MeSH terms with a common part that focused on HADs and a disease-specific part. All identified papers were screened by two independent reviewers. Pertinent papers were classified according to the objective for which the algorithm had been used, and only articles that used algorithms for primary objectives (I disease occurrence; II population/cohort selection; III outcome identification) were considered for algorithm extraction. The HADs used (hospital discharge records, drug prescriptions, etc.), ICD-9 and ICD-10 codes, ATC classification of drugs, follow-back periods, and age ranges applied by the algorithms have been reported. Further information on specific objective(s), accuracy measures, sensitivity analyses and the contribution of each HAD, have also been recorded. Results: the search strategy has led to the identification of 611 papers for AMI,801 for IHDs and 791 for stroke. Among these,45,12 and 31 papers for AMI, IHDs and stroke respectively, were considered pertinent for inclusion in the systematic review. The majority of the works was published during 2014-2017. The setting of the studies was mainly regional for AMI and stroke, while the majority of IHD’s papers was based on a national multicenter context. By screening full texts, a total of 17,5 and 28 original algorithms for AMI, IHDs and stroke respectively, intended for the above-mentioned objectives, were found. Moreover, 3 original algorithms for STEMI, 3 for NSTEMI, 8 for ischemic stroke and 3 for hemorrhagic stroke were identified. The hospital discharge diagnosis database (HDD) was used in all algorithms. In only a few cases the co-payment exemption registry, drug prescription database, and mortality registry database were used as additional algorithm components. For the same event, there was always a difference of >1 code. External validation was performed in only one case for AMI and stroke identification. Conclusion: a remarkable heterogeneity, in terms of both data sources and codes used, was observed for algorithms aimed to identify AMI, IHDs and stroke in HADs. This was likely due to the paucity of validation studies. Administrative data sources other than HDD remain underutilized.
- Published
- 2019
28. A Systematic Review of Case-Identification Algorithms for 18 Conditions Based on Italian Healthcare Administrative Databases: A Study Protocol
- Author
-
Canova C., Simonato L., Barbiellini Amidei C., Baldi I., Dalla Zuanna T., Gregori D., Danieli S., Buja A., Lorenzoni G., Pitter G., Costa G., Gnavi R., Corrao G., Rea F., Gini R., Hyeraci G., Roberto G., Spini A., Lucenteforte E., Agabiti N., Davoli M., Di Domenicantonio R., Cappai G., Canova, C, Simonato, L, Barbiellini Amidei, C, Baldi, I, Dalla Zuanna, T, Gregori, D, Danieli, S, Buja, A, Lorenzoni, G, Pitter, G, Costa, G, Gnavi, R, Corrao, G, Rea, F, Gini, R, Hyeraci, G, Roberto, G, Spini, A, Lucenteforte, E, Agabiti, N, Davoli, M, Di Domenicantonio, R, and Cappai, G
- Subjects
Databases, Factual ,Italy ,Research Design ,Acute Disease ,Chronic Disease ,Humans ,Algorithms, Healthcare administrative database ,Algorithms ,Health Services Administration ,Systematic Reviews as Topic - Abstract
BACKGROUND: there has been a long-standing, consistent use worldwide of Healthcare Administrative Databases (HADs) for epidemiological purposes, especially to identify acute and chronic health conditions. These databases are able to reflect health-related conditions at a population level through disease-specific case-identification algorithms that combine information coded in multiple HADs. In Italy, in the past 10 years, HAD-based case-identification algorithms have experienced a constant increase, with a significant extension of the spectrum of identifiable diseases. Besides estimating incidence and/or prevalence of diseases, these algorithms have been used to enroll cohorts, monitor quality of care, assess the effect of environmental exposure, and identify health outcomes in analytic studies. Despite the rapid increase in the use of case-identification algorithms, information on their accuracy and misclassification rate is currently unavailable for most conditions. OBJECTIVES: to define a protocol to systematically review algorithms used in Italy in the past 10 years for the identification of several chronic and acute diseases, providing an accessible overview to future users in the Italian and international context. METHODS: PubMed will be searched for original research articles, published between 2007 and 2017, in Italian or English. The search string consists of a combination of free text and MeSH terms with a common part on HADs and a disease-specific part. All identified papers will be screened for eligibility by two independent reviewers. All articles that used/defined an algorithm for the identification of each disease of interest using Italian HADs will be included. Algorithms with exclusive use of death certificates, pathology register, general practitioner or pediatrician data will be excluded. Pertinent papers will be classified according to the objective for which the algorithm was used, and only articles that used algorithms with "primary objectives" (I disease occurrence; II population/cohort selection; III outcome identification) will be considered for algorithm extraction. The HADs used (hospital discharge records, drug prescriptions, etc.), ICD-9 and ICD-10 codes, ATC classification of drugs, follow-back periods, and age ranges applied by the algorithms will be collected. Further information on specific accuracy measures from external validations, sensitivity analyses, and the contribution of each source will be recorded. This protocol will be applied for 16 different systematic reviews concerning eighteen diseases (Hypothyroidism, Hyperthyroidism, Diabetes mellitus, Type 1 diabetes mellitus, Acute myocardial infarction, Ischemic heart disease, Stroke, Hypertension, Heart failure, Congenital heart anomalies, Parkinson's disease, Multiple sclerosis, Epilepsy, Chronic obstructive pulmonary disease, Asthma, Inflammatory bowel disease, Celiac disease, Chronic kidney failure). CONCLUSION: this protocol defines a standardized approach to extensively examine and compare all experiences of case identification algorithms in Italy, on the 18 abovementioned diseases. The methodology proposed may be applied to other systematic reviews concerning diseases not included in this project, as well as other settings, including international ones. Considering the increasing availability of healthcare data, developing standard criteria to describe and update characteristics of published algorithms would be of great use to enhance awareness in the choice of algorithms and provide a greater comparability of results.
- Published
- 2019
29. Bleeding events attributable to concurrent use of warfarin and other medications in high-risk elderly: meta-analysis and Italian population-based investigation
- Author
-
Comoretto, R, Rea, F, Lucenteforte, E, Mugelli, A, Trifiro, G, Cascini, S, Roberto, G, Chinellato, A, Filippelli, A, Corrao, G, Comoretto R. I., Rea F., Lucenteforte E., Mugelli A., Trifiro G., Cascini S., Roberto G., Chinellato A., Filippelli A., Corrao G., Comoretto, R, Rea, F, Lucenteforte, E, Mugelli, A, Trifiro, G, Cascini, S, Roberto, G, Chinellato, A, Filippelli, A, Corrao, G, Comoretto R. I., Rea F., Lucenteforte E., Mugelli A., Trifiro G., Cascini S., Roberto G., Chinellato A., Filippelli A., and Corrao G.
- Abstract
Purpose: The aim of this study was to estimate the proportion of bleedings that occurred among warfarin users attributable to the concomitant use of other medications. A general approach for measuring the impact of the prescriptive inappropriateness on drug adverse outcomes at the population level is described. Methods: A meta-analysis was conducted to obtain summary relative risks of bleeding associated with concurrent use of warfarin and other medications compared to warfarin use alone. A population-based investigation was performed, in an Italian cohort of cardiopathic patients aged 65 years or older, to estimate the prevalence of concurrent users of warfarin and other medicaments. The population attributable fraction was computed by combining data on summary relative risks and prevalence of concurrent users. Results: Concomitant use of warfarin and cotrimoxazole, amiodarone, quinolones, macrolides, platelet aggregation inhibitors, SSRIs, NSAIDs, and lipid-lowering agents was associated with an increased risk of bleeding. The corresponding attributable fractions were 3% (95% CI 2 to 4%), 21% (1 to 41%), 21% (17 to 25%), 9% (8 to 10%), 14% (12 to 16%), 6% (5 to 8%), 10% (1 to 20%), and 8% (0 to 18%), respectively. Conclusions: More than half of bleeding events occurring among frail elderly using warfarin are attributable to a concomitant use of warfarin with certain drugs. Because some of these drugs appear to be essential for the treatment/prevention of cardiovascular conditions, and their concomitant use with warfarin could be acceptable in some cases, proper INR-monitoring and warfarin dose adjustments are requested.
- Published
- 2018
30. Antidepressants and the risk of arrhythmia in elderly affected by a previous cardiovascular disease: a real-life investigation from Italy
- Author
-
Biffi, A, Rea, F, Scotti, L, Mugelli, A, Lucenteforte, E, Bettiol, A, Chinellato, A, Onder, G, Vitale, C, Agabiti, N, Trifirã2, G, Roberto, G, Corrao, G, Biffi, A., Rea, F., Scotti, L., Mugelli, A., Lucenteforte, E., Bettiol, A., Chinellato, A., Onder, G., Vitale, C., Agabiti, N., TrifirÃ2, G., Roberto, G., Corrao, G., Biffi, A, Rea, F, Scotti, L, Mugelli, A, Lucenteforte, E, Bettiol, A, Chinellato, A, Onder, G, Vitale, C, Agabiti, N, Trifirã2, G, Roberto, G, Corrao, G, Biffi, A., Rea, F., Scotti, L., Mugelli, A., Lucenteforte, E., Bettiol, A., Chinellato, A., Onder, G., Vitale, C., Agabiti, N., TrifirÃ2, G., Roberto, G., and Corrao, G.
- Abstract
Purpose: The study aimed to fill existing knowledge gaps on the safety of antidepressant drugs (ADs) by estimating the risk of hospitalization for arrhythmia associated with use of selective serotonin reuptake inhibitors (SSRIs) and newer atypical ADs (NAAs) among elderly with previous cardiovascular (CV) events. Methods: The cohort was composed by 199,569 individuals aged ≥ 65 years from five Italian healthcare territorial units who were discharged for cardiovascular outcomes in the years 2008–2010. The 17,277 patients who experienced hospital admission for arrhythmia during follow-up were included as cases. Odds of current ADs use among cases (i.e., 14 days before hospital admission) was compared with (i) odds of current use of 1:5 matched controls (between-patients case-control) and with (ii) odds of previous use during 1:5 matched control periods (within-patient case-crossover). The risk of arrhythmia associated with ADs current use was modelled fitting a conditional logistic regression. A set of sensitivity analyses was performed to account for sources of systematic uncertainty. Results: Current users of SSRIs and NAAs were at increased risk of arrhythmia with case-control odds ratios (OR) of 1.37 (95% confidence interval, CI 1.18 to 1.58) and 1.41 (1.16 to 1.71) and case-crossover OR of 1.48 (1.20 to 1.81) and 1.72 (1.31 to 2.27). An increased risk of arrhythmia was associated with current use of trazodone (NAA) consistently in case-control and case-crossover designs. Conclusions: Evidence that current use of SSRIs and NAAs is associated to an increased risk of arrhythmia among elderly with CV disease was consistently supplied by two observational approaches.
- Published
- 2018
31. Validazione degli algoritmi di selezione dei pazienti reumatologici nei database amministrativi toscani e traiettorie di aderenza ai farmaci biologici modificanti la malattia nell’artrite reumatoide
- Author
-
Fornili, M., Blandizzi, C., Lucenteforte, E., Gini, R., Mosca, M., Cazzato, M., Filippi, M., Cristofano, M., Turchetti, G., Trieste, L., and Lorenzoni, V.
- Published
- 2020
32. Valutazione dei pazienti affetti da artrite reumatoide utilizzatori di JAK inibitori in Toscana con riferimento all’accesso ai servizi sanitari e ai costi associati: lo studio LEONARDO
- Author
-
Giometto, S., Lucenteforte, E., Convertino, I., Ferraro, S., Cappello, E., Valdiserra, G., Blandizzi, C., Tuccori, M., Lorenzoni, V., Turchetti, G., Gini, R., Bartolini, C., and Paoletti, O.
- Published
- 2020
33. Ultrathin Descemet stripping automated endothelial keratoplasty versus Descemet membrane endothelial keratoplasty: a fellow-eye comparison
- Author
-
Mencucci, R., Favuzza, E., Marziali, Eleonora, Cennamo, M., Mazzotta, Maria Chiara, Lucenteforte, E., Virgili, Gianni, Rizzo, Stanislao, Marziali E., Mazzotta C. (ORCID:0000-0003-2487-774X), Virgili G., Rizzo S. (ORCID:0000-0001-6302-063X), Mencucci, R., Favuzza, E., Marziali, Eleonora, Cennamo, M., Mazzotta, Maria Chiara, Lucenteforte, E., Virgili, Gianni, Rizzo, Stanislao, Marziali E., Mazzotta C. (ORCID:0000-0003-2487-774X), Virgili G., and Rizzo S. (ORCID:0000-0001-6302-063X)
- Abstract
Background: To compare the visual outcome and patients’ satisfaction after ultrathin Descemet stripping automated endothelial keratoplasty (UT-DSAEK) and Descemet membrane endothelial keratoplasty (DMEK) performed on fellow eyes of the same patients. Methods: In this retrospective study, the records of 18 pseudophakic patients affected by Fuchs endothelial dystrophy who underwent DMEK in one eye and UT-DSAEK in the fellow eye were reviewed. Best corrected visual acuity (BCVA), corneal pachymetry, keratometry, corneal aberrations, photopic and mesopic contrast sensitivity, and endothelial cell counts measured 12 months after surgery in either eye were analyzed and compared. The results of a satisfaction questionnaire were also reviewed. Results: Twelve months after surgery, BCVA was not significantly different in UT-DSAEK and DMEK eyes (0.10 ± 0.04 and 0.07 ± 0.07 logMAR, respectively); at both 4- and 6 mm optical zones total and posterior corneal higher order aberrations (HOAs), posterior astigmatism and total coma were significantly lower after DMEK; BCVA in both groups was significantly correlated mainly with anterior corneal aberrations; contrast sensitivity was higher after DMEK especially in mesopic conditions and at medium spatial frequencies; the endothelial cell density was similar, although slightly higher in the UT-DSAEK group (p = 0.10). The satisfaction questionnaire showed that although patients were highly satisfied from both procedures, more than half of them preferred DMEK and reported a more comfortable and quicker postoperative recovery. Conclusions: DMEK and UT-DSAEK showed no evidence of difference in terms of postoperative BCVA, although DMEK had a better performance in terms of contrast sensitivity, posterior corneal aberrations and overall patient satisfaction.
- Published
- 2020
34. P.462 Metabolic disorders induced by antipsychotic drugs: clinical findings in support of non-psychopharmacological mechanisms of action
- Author
-
Carnovale, C., primary, Lucenteforte, E., additional, Battini, V., additional, Mazhar, F., additional, Fornili, M., additional, Invernizzi, E., additional, Mosini, G., additional, Gringeri, M., additional, Pisano, S., additional, and Pozzi, M., additional
- Published
- 2020
- Full Text
- View/download PDF
35. Alcohol consumption and pancreatic cancer: a pooled analysis in the International Pancreatic Cancer Case–Control Consortium (PanC4)
- Author
-
Lucenteforte, E., La Vecchia, C., Silverman, D., Petersen, G. M., Bracci, P. M., Ji, B. T., Bosetti, C., Li, D., Gallinger, S., Miller, A. B., Bueno-de-Mesquita, H. B., Talamini, R., Polesel, J., Ghadirian, P., Baghurst, P. A., Zatonski, W., Fontham, E., Bamlet, W. R., Holly, E. A., Gao, Y. T., Negri, E., Hassan, M., Cotterchio, M., Su, J., Maisonneuve, P., Boffetta, P., and Duell, E. J.
- Published
- 2012
- Full Text
- View/download PDF
36. Reply to Are cohort data on smokeless tobacco use and pancreatic cancer confounded by alcohol use?
- Author
-
Bertuccio, P., La Vecchia, C., Silverman, D. T., Petersen, G. M., Bracci, P. M., Negri, E., Li, D., Risch, H. A., Olson, S. H., Gallinger, S., Miller, A. B., Bueno-de-Mesquita, H. B., Talamini, R., Polesel, J., Ghadirian, P., Baghurst, P. A., Zatonski, W., Fontham, E., Bamlet, W. R., Holly, E. A., Lucenteforte, E., Hassan, M., Yu, H., Kurtz, R. C., Cotterchio, M., Su, J., Maisonneuve, P., Duell, E. J., Bosetti, C., and Boffetta, P.
- Published
- 2011
- Full Text
- View/download PDF
37. Systematic review on Screening for antimicrobial-resistant Gram-negative bacteria in inpatients
- Author
-
Scardina, G, primary, Arzilli, G, additional, Casigliani, V, additional, Moi, M, additional, Lucenteforte, E, additional, Petri, D, additional, Rello, J, additional, Manissero, D, additional, Lopalco, P L, additional, and Tavoschi, L, additional
- Published
- 2020
- Full Text
- View/download PDF
38. Risk of infection in antimicrobial-resistant Gram-negative bacteria carriers: A systematic review
- Author
-
Arzilli, G, primary, Scardina, G, additional, Casigliani, V, additional, Moi, M, additional, Lucenteforte, E, additional, Petri, D, additional, Rello, J, additional, Manissero, D, additional, Lopalco, P L, additional, and Tavoschi, L, additional
- Published
- 2020
- Full Text
- View/download PDF
39. PBI90 THE ECONOMIC IMPACT OF THE INTRODUCTION OF INFLIXIMAB-BIOSIMILAR: AN EMPIRICAL ANALYSIS USING THE TUSCANY HEALTHCARE ADMINISTRATIVE DATABASES
- Author
-
Lorenzoni, V., primary, Convertino, I., additional, Lucenteforte, E., additional, Ferraro, S., additional, Leonardi, L., additional, Roberto, G., additional, Luciano, N., additional, Cazzato, M., additional, Blandizzi, C., additional, Gini, R., additional, Tuccori, M., additional, Mosca, M., additional, and Turchetti, G., additional
- Published
- 2019
- Full Text
- View/download PDF
40. Adherence of Elderly Patients with Cardiovascular Disease to Statins and the Risk of Exacerbation of Chronic Obstructive Pulmonary Disease: Evidence from an Italian Real-World Investigation
- Author
-
Rea, F, Calusi, G, Franchi, M, Vetrano, Dl, Roberto, G, Bonassi, S, Kirchmayer, U, Chinellato, A, Bettiol, A, Sultana, J, Mugelli, A, Corrao, G, Agabiti, N, Bartolini, C, Bernabei, Rita, Caputi, Ap, Cascini, S, Cipriani, F, Davoli, M, Fini, M, Gini, R, Giorgianni, F, Lapi, F, Lombardi, N, Lucenteforte, E, Onder, G, Sorge, C, Tari, M, Trifirò, G, Vannacci, A, Vitale, C., Rea, F, Calusi, G, Franchi, M, Vetrano, D, Borloni, R, Bonassi, S, Kirchmayer, U, Chinellato, A, Bettiol, A, Sultana, J, Mugelli, A, Corrao, G, Agabiti, N, Bartolini, C, Bernabei, R, Caputi, A, Cascini, S, Cipriani, F, Davoli, M, Fini, M, Gini, R, Giorgianni, F, Lapi, F, Lombardi, N, Lucenteforte, E, Onder, G, Sorge, C, Tari, M, Trifirò, G, Vannacci, A, and Vitale, C
- Subjects
Male ,medicine.medical_specialty ,Exacerbation ,Disease ,Lower risk ,Medication Adherence ,Geriatrics and Gerontology ,Pharmacology (medical) ,Cohort Studies ,03 medical and health sciences ,Pulmonary Disease, Chronic Obstructive ,0302 clinical medicine ,Internal medicine ,Medicine ,Humans ,030212 general & internal medicine ,Aged ,Aged, 80 and over ,Cardiovascular Diseases ,Female ,Hospitalization ,Hydroxymethylglutaryl-CoA Reductase Inhibitors ,Italy ,Proportional Hazards Models ,business.industry ,Proportional hazards model ,Hazard ratio ,Confidence interval ,030228 respiratory system ,Cohort ,business ,Cohort study - Abstract
Objective: The objective of this study was to investigate the relationship between adherence to statin therapy and the risk of exacerbation among elderly individuals affected by chronic obstructive pulmonary disease and cardiovascular disease. Methods: Using the healthcare utilisation databases of five Italian territorial units accounting for nearly 35% of the Italian population, we recruited a cohort of 6263 elderly persons (i.e. aged 65 years or older) with co-existing chronic obstructive pulmonary disease and cardiovascular disease who initiated statin therapy. Exposure was adherence to statins measured by the proportion of days of follow-up covered. Outcome was the first hospital admission for chronic obstructive pulmonary disease occurring in the period of observation. A proportional hazards model was used to estimate the hazard ratio and 95% confidence intervals for the exposure–outcome association, after adjusting for several covariates. A set of sensitivity analyses was performed to account for sources of systematic uncertainty. Results: During an average follow-up of about 4 years, 1307 cohort members experienced the outcome. Compared with patients with low adherence (proportion of days of follow-up covered ≤ 40%), those with intermediate (proportion of days of follow-up covered 41–80%) and high (proportion of days of follow-up covered > 80%) adherence exhibited a lower risk of exacerbation of 16% (95% confidence interval 3–27) and 23% (95% confidence interval 10–34). Conclusions: In a real-world setting, we observed evidence that adherence to statin therapy markedly reduced the risk of chronic obstructive pulmonary disease exacerbations in elderly patients with co-existing chronic obstructive pulmonary disease and cardiovascular disease. Given the limited and controversial evidence from trials, more randomised controlled trials are urgently needed to better examine the potential benefits of statins as adjunct therapy in chronic obstructive pulmonary disease.
- Published
- 2018
41. Adherence to Antidepressants and Mortality in Elderly Patients with Cardiovascular Disease
- Author
-
Biffi, A, Scotti, L, Rea, F, Lucenteforte, E, Chinellato, A, Vetrano, Dl, Vitale, C, Agabiti, N, Sultana, J, Roberto, G, Mugelli, A, G Agabiti N, Corrao, Bartolini, C, Bernabei, R, Bettiol, A, Bonassi, S, Caputi, Ap, Cascini, S, Cipriani, F, Corrao, G, Davoli, M, Fini, M, Gini, R, Giorgianni, F, Kirchmayer, U, Lapi, F, Lombardi, N, Onder, G, Sorge, C, Tari, M, Trifirò, G, Vannacci, A, Vitale, C., Biffi, A, Scotti, L, Rea, F, Lucenteforte, E, Chinellato, A, Vetrano, D, Vitale, C, Agabiti, N, Sultana, J, Roberto, G, Mugelli, A, and Corrao, G
- Subjects
Male ,medicine.medical_specialty ,Databases, Factual ,MEDLINE ,Antidepressant ,Disease ,030204 cardiovascular system & hematology ,Medication Adherence ,Cohort Studies ,03 medical and health sciences ,Databases ,0302 clinical medicine ,Pharmacotherapy ,Internal medicine ,80 and over ,Medicine ,Humans ,Pharmacology (medical) ,030212 general & internal medicine ,Medical prescription ,Mortality ,Factual ,Antihypertensive Agents ,Aged ,Aged, 80 and over ,Antidepressive Agents ,Cardiovascular Diseases ,Female ,Follow-Up Studies ,Italy ,business.industry ,Proportional hazards model ,General Medicine ,Cardiovascular disease ,Adherence ,Cohort ,business ,Cohort study - Abstract
Background and Objective: Conflicting findings from studies evaluating the association between use of antidepressant drugs and mortality have been reported. We tested the hypothesis that better adherence to antidepressant therapy may reduce mortality. Methods: The cohort included 29,845 individuals aged ≥ 65 years from several Italian health units who were newly treated with antidepressant drugs after hospital discharge with a diagnosis for cardiovascular disease during 2008–2010. These individuals were observed from the first prescription until the end of data availability (i.e. 2012–2014, depending on the local database). During this period, information on (1) prescription of antidepressants and other medications and (2) death from any cause (outcome) was recorded. Proportional hazards models were fitted to estimate the association between better adherence to antidepressants (defined as proportion of days covered ≥ 75%) and outcome, by adjusting and stratifying for several covariates. Results: Patients with better adherence to antidepressants had a reduced mortality of 9% (95% CI 3–14). Patients who did not use other medicaments during follow-up had reduced mortality associated with better adherence to antidepressants of 21% (− 1–38), 14% (7–20), 20% (13–26) and 13% (7–19) for no users of antihypertensive agents, lipid-lowering agents, other cardiovascular drugs and antidiabetics, respectively. Conclusions: Better adherence to antidepressants is associated with reduced all-cause mortality, mainly in patients who did not use other pharmacological treatments. Behavioural changes to enhance adherence among the elderly with cardiovascular disease might offer important benefits in reducing their mortality.
- Published
- 2018
42. NSAIDs utilization for musculoskeletal indications in elderly patients with cerebro/cardiovascular disease
- Author
-
Roberto, G., Bartolini, C., Rea, Federico, Onder, G., Vitale, C., Trifirò, G., Kirchmayer, U., Chinellato, A., Lucenteforte, E., Corrao, G., Mugelli, A., Lapi, F., Gini, R., Agabiti, N., Bernabei, R., Bettiol, A., Bonassi, S., Caputi, A. P., Cascini, S., Davoli, M., Fini Storchi, Marco, Giorgianni, F., Lombardi, N., Rea, F., Sorge, C., Tari, M., Vannacci, A., Vetrano, D. L., Vitale, Claudia, Roberto, G, Bartolini, C, Rea, F, Onder, G, Vitale, C, Trifirò, G, Kirchmayer, U, Chinellato, A, Lucenteforte, E, Corrao, G, Mugelli, A, Lapi, F, Gini, R, On Behalf Of The Italian Group For Appropriate Drug Prescription In The Elderly (I-Grade): Agabiti, N, Bernabei, R, Bettiol, A, Bonassi, S, Caputi, A, Cascini, S, Davoli, M, Fini, M, Giorgianni, F, Lombardi, N, Sorge, C, Tari, M, Vannacci, A, and Vetrano, D
- Subjects
Drug Utilization ,medicine.medical_specialty ,Diclofenac ,Pharmacoepidemiology and Prescription ,NSAIDs ,Population ,Psychological intervention ,Cardiovascular risk Coxibs Diclofenac Drug utilization Elderly NSAIDs ,Disease ,030204 cardiovascular system & hematology ,Coxib ,03 medical and health sciences ,0302 clinical medicine ,Elderly ,Internal medicine ,medicine ,Coxibs ,Drug utilization ,Humans ,Pharmacology (medical) ,Musculoskeletal Diseases ,030212 general & internal medicine ,Medical prescription ,education ,Aged ,Aged, 80 and over ,Pharmacology ,education.field_of_study ,business.industry ,Anti-Inflammatory Agents, Non-Steroidal ,General Medicine ,Cardiovascular risk ,NSAID ,Cardiovascular Diseases ,Cohort ,Female ,business ,Nimesulide ,medicine.drug - Abstract
Objectives To describe NSAID utilization for musculoskeletal conditions in a large cohort of Italian elderly with cerebro/cardiovascular disease, a population in which NSAIDs should be generally avoided due to the prothrombotic potential. Methods Administrative data from five Italian geographic areas were analyzed. Patients aged ≥ 65 with a cerebro/cardiovascular event recorded between 2008 and 2011 (cohort entry) were selected. Prescription NSAIDs reimbursed for musculoskeletal conditions and dispensed during 1 year follow-up were retrieved to describe (i) prevalence of use, (ii) average amount of defined daily doses of NSAIDs claimed by users per day of follow-up, and (iii) distribution of the received daily dose (RDD) among patients with ≥ 2 dispensings. Among new users, i.e., patients without NSAID dispensings during 2 years before cohort entry, the first dispensed NSAID molecule was observed. Results Overall, 511,989 patients were selected. Across the five geographic areas, prevalence of use ranged from 48 to 21% and average consumption ranged between 30 and 67 DDD/1000 users/day. Around 10% of patients in the overall cohort had a RDD > 1. Nimesulide (9.6%) and diclofenac (7.5%) had the highest prevalence of use. The most consumed NSAIDs were nimesulide and coxibs with 10.6 and 7.5 DDD/1000 users/day, respectively. Among new users recruited in 2011, 30% had diclofenac or a coxibs as the first prescription. Conclusions NSAID use was common in the study cohort, particularly in central-southern areas. In contrast with current recommendations, coxibs and diclofenac were among the most prescribed active principles, even in new users. Interventions to promote appropriateness of use are warranted. Electronic supplementary material The online version of this article (10.1007/s00228-018-2411-y) contains supplementary material, which is available to authorized users.
- Published
- 2018
43. Trends in pediatric epilepsy surgery in Europe between 2008 and 2015: Country-, center-, and age-specific variation
- Author
-
Barba, C., Cross, J. H., Braun, K., Cossu, M., Klotz, K. A., De Masi, S., Perez Jimenez, M. A., Gaily, E., Specchio, N., Cabral, P., Toulouse, J., Dimova, P., Battaglia, D., Freri, E., Consales, A., Cesaroni, E., Tarta-Arsene, O., Gil-Nagel, A., Mindruta, I., Di Gennaro, G., Giulioni, M., Tisdall, M. M., Eltze, C., Tahir, M. Z., Jansen, F., van Rijen, P., Sanders, M., Tassi, L., Francione, S., Lo Russo, G., Jacobs, J., Bast, T., Matta, G., Budke, M., Fournier del Castillo, C., Metsahonkala, E. -L., Karppinen, A., Ferreira, J. C., Minkin, K., Marras, C. E., Lucenteforte, E, Arzimanoglou, A., and Guerrini, R.
- Subjects
0301 basic medicine ,Male ,medicine.medical_specialty ,Multivariate analysis ,Adolescent ,Neurosurgery ,Stereoelectroencephalography ,Neurosurgical Procedures ,03 medical and health sciences ,Epilepsy ,Settore MED/39 - NEUROPSICHIATRIA INFANTILE ,0302 clinical medicine ,children ,Seizures ,Medicine ,Humans ,survey ,Epilepsy surgery ,Preschool ,Child ,Retrospective Studies ,medicine.diagnostic_test ,business.industry ,Age Factors ,Magnetic resonance imaging ,Retrospective cohort study ,Electroencephalography ,medicine.disease ,Magnetic Resonance Imaging ,Temporal Lobe ,3. Good health ,Surgery ,Europe ,epilepsy surgery ,histopathology ,outcome ,Child, Preschool ,Female ,Treatment Outcome ,030104 developmental biology ,Neurology ,Histopathology ,Neurology (clinical) ,business ,030217 neurology & neurosurgery - Abstract
OBJECTIVE: To profile European trends in pediatric epilepsy surgery (
- Published
- 2019
44. Management of psychogenic nonepileptic seizures (PNES): a multidisciplinary approach
- Author
-
Gasparini, S, Beghi, E, Ferlazzo, E, Beghi, M, Belcastro, V, Biermann, Kp, Bottini, G, Capovilla, G, Cervellione, Ra, Cianci, V, Coppola, G, Cornaggia, Cm, De Fazio, P, De Masi, S, De Sarro, G, Elia, M, Erba, G, Fusco, L, Gambardella, A, Gentile, V, Giallonardo, At, Guerrini, R, Ingravallo, F, Iudice, A, Labate, A, Lucenteforte, E, Magaudda, A, Mumoli, L, Papagno, C, Pesce, Gb, Pucci, E, Ricci, P, Romeo, A, Quintas, R, Sueri, C, Vitaliti, G, Zoia, R, and Aguglia, U.
- Subjects
EEG ,conversion disorder ,epilepsy - Published
- 2019
45. Diagnostic implications of genetic copy number variation in epilepsy plus
- Author
-
Coppola, A., Cellini, E., Stamberger, H., Saarentaus, E., Cetica, V., Lal, D., Djemie, T., Bartnik-Glaska, M., Ceulemans, B., Helen Cross, J., Deconinck, T., Masi, S. D., Dorn, T., Guerrini, R., Hoffman-Zacharska, D., Kooy, F., Lagae, L., Lench, N., Lemke, J. R., Lucenteforte, E., Madia, F., Mefford, H. C., Morrogh, D., Nuernberg, P., Palotie, A., Schoonjans, A. -S., Striano, P., Szczepanik, E., Tostevin, A., Vermeesch, J. R., Van Esch, H., Van Paesschen, W., Waters, J. J., Weckhuysen, S., Zara, F., Jonghe, P. D., Sisodiya, S. M., Marini, C., Lehesjioki, A. -E., Craiu, D., Talvik, T., Caglayan, H., Serratosa, J., Sterbova, K., Moller, R. S., Hjalgrim, H., Lerche, H., Weber, Y., Helbig, I., von Spiczak, S., Barba, C., Bogaerts, A., Boni, A., Galizia, E. C., Chiari, S., Di Gacomo, G., Ferrari, A., Guarducci, S., Giglio, S., Holmgren, P., Leu, C., Melani, F., Novara, F., Pantaleo, M., Peeters, E., Pisano, T., Rosati, A., Sander, J., Schoeler, N., Stankiewicz, P., Striano, S., Suls, A., Traverso, M., Vandeweyer, G., Van Dijck, A., Zuffardi, O., Coppola, Antonietta, Cellini, Elena, Stamberger, Hannah, Saarentaus, Elmo, Cetica, Valentina, Lal, Denni, Djémié, Tania, Bartnik-Glaska, Magdalena, Ceulemans, Berten, Helen Cross, J., Deconinck, Tine, Masi, Salvatore De, Dorn, Thoma, Guerrini, Renzo, Hoffman-Zacharska, Dorotha, Kooy, Frank, Lagae, Lieven, Lench, Nichola, Lemke, Johannes R., Lucenteforte, Ersilia, Madia, Francesca, Mefford, Heather C., Morrogh, Deborah, Nuernberg, Peter, Palotie, Aarno, Schoonjans, An-Sofie, Striano, Pasquale, Szczepanik, Elzbieta, Tostevin, Anna, Vermeesch, Joris R., Van Esch, Hilde, Van Paesschen, Wim, Waters, Jonathan J, Weckhuysen, Sarah, Zara, Federico, Jonghe, Peter De, Sisodiya, Sanjay M., Marini, Carla, Lehesjioki, Anna-Elina, Craiu, Dana, Talvik, Tiina, Caglayan, Hande, Serratosa, Jose, Sterbova, Katalin, Møller, Rikke S., Hjalgrim, Helle, Lerche, Holger, Weber, Yvonne, Helbig, Ingo, von Spiczak, Sarah, Barba, Carmen, Bogaerts, Anneleen, Boni, Antonella, Galizia, Elisabeth Caruana, Chiari, Sara, Di Gacomo, Gianpiero, Ferrari, Annarita, Guarducci, Silvia, Giglio, Sabrina, Holmgren, Philip, Leu, Costin, Melani, Federico, Novara, Francesca, Pantaleo, Marilena, Peeters, Elke, Pisano, Tiziana, Rosati, Anna, Sander, Josemir, Schoeler, Natasha, Stankiewicz, Pawel, Striano, Salvatore, Suls, Arvid, Traverso, Monica, Vandeweyer, Geert, Van Dijck, Anke, and Zuffardi, Orsetta
- Subjects
epilepsy gene ,Epilepsy ,DNA Copy Number Variations ,Genotype ,Comorbidity ,array CGH ,copy number variants ,epilepsy genes ,SNP array ,Phenotype ,Neurology ,mental disorders ,Full‐length Original Research ,Humans ,copy number variant ,Genetic Predisposition to Disease ,Neurology (clinical) - Abstract
Summary Objective Copy number variations (CNVs) represent a significant genetic risk for several neurodevelopmental disorders including epilepsy. As knowledge increases, reanalysis of existing data is essential. Reliable estimates of the contribution of CNVs to epilepsies from sizeable populations are not available. Methods We assembled a cohort of 1255 patients with preexisting array comparative genomic hybridization or single nucleotide polymorphism array based CNV data. All patients had “epilepsy plus,” defined as epilepsy with comorbid features, including intellectual disability, psychiatric symptoms, and other neurological and nonneurological features. CNV classification was conducted using a systematic filtering workflow adapted to epilepsy. Results Of 1097 patients remaining after genetic data quality control, 120 individuals (10.9%) carried at least one autosomal CNV classified as pathogenic; 19 individuals (1.7%) carried at least one autosomal CNV classified as possibly pathogenic. Eleven patients (1%) carried more than one (possibly) pathogenic CNV. We identified CNVs covering recently reported (HNRNPU) or emerging (RORB) epilepsy genes, and further delineated the phenotype associated with mutations of these genes. Additional novel epilepsy candidate genes emerge from our study. Comparing phenotypic features of pathogenic CNV carriers to those of noncarriers of pathogenic CNVs, we show that patients with nonneurological comorbidities, especially dysmorphism, were more likely to carry pathogenic CNVs (odds ratio = 4.09, confidence interval = 2.51‐6.68; P = 2.34 × 10−9). Meta‐analysis including data from published control groups showed that the presence or absence of epilepsy did not affect the detected frequency of CNVs. Significance The use of a specifically adapted workflow enabled identification of pathogenic autosomal CNVs in 10.9% of patients with epilepsy plus, which rose to 12.7% when we also considered possibly pathogenic CNVs. Our data indicate that epilepsy with comorbid features should be considered an indication for patients to be selected for a diagnostic algorithm including CNV detection. Collaborative large‐scale CNV reanalysis leads to novel declaration of pathogenicity in unexplained cases and can promote discovery of promising candidate epilepsy genes.
- Published
- 2019
46. Farmaci per le patologie autoimmuni. Traiettorie di trattamento nell’artrite reumatoide
- Author
-
Lucenteforte, E., Convertino, I., Giometto, S., Ferraro, S., Fornili, M., Blandizzi, C., Tuccori, M., Gini, R., Mosca, M., Cazzato, M., Turchetti, G., Lorenzoni, V., and Trieste, L.
- Published
- 2019
47. THE ECONOMIC IMPACT OF THE INTRODUCTION OF INFLIXIMAB-BIOSIMILAR: AN EMPIRICAL ANALYSIS USING THE TUSCANY HEALTHCARE ADMINISTRATIVE DATABASES
- Author
-
Lorenzoni, V., Convertino, I., Lucenteforte, E., Ferraro, S., Leonardi, L., Roberto, G., Luciano, N., Cazzato, M., Blandizzi, C., Rosa Gini, Tuccori, M., Mosca, M., and Turchetti, G.
- Published
- 2019
48. Bisphosphonates and cardiovascular risk in elderly patients with previous cardiovascular disease: a population-based nested case-control study in Italy
- Author
-
Kirchmayer, U, Sorge, C, Sultana, J, Lapi, F, Onder, G, Agabiti, N, Cascini, S, Roberto, G, Corrao, G, Vitale, C, Lucenteforte, E, Mugelli, A, Davoli, M, Kirchmayer, Ursula, Sorge, Chiara, Sultana, Janet, Lapi, Francesco, Onder, Graziano, Agabiti, Nera, Cascini, Silvia, Roberto, Giuseppe, Corrao, Giovanni, Vitale, Cristiana, Lucenteforte, Ersilia, Mugelli, Alessandro, Davoli, Marina, Kirchmayer, U, Sorge, C, Sultana, J, Lapi, F, Onder, G, Agabiti, N, Cascini, S, Roberto, G, Corrao, G, Vitale, C, Lucenteforte, E, Mugelli, A, Davoli, M, Kirchmayer, Ursula, Sorge, Chiara, Sultana, Janet, Lapi, Francesco, Onder, Graziano, Agabiti, Nera, Cascini, Silvia, Roberto, Giuseppe, Corrao, Giovanni, Vitale, Cristiana, Lucenteforte, Ersilia, Mugelli, Alessandro, and Davoli, Marina
- Abstract
Background: In a globally aging population, chronic conditions with a high impact on healthcare costs and quality of life, such as osteoporosis and associated fractures, are a matter of concern. For osteoporosis, several drug treatments are available, but evidence on adverse cardiovascular and cerebrovascular (CCV) events, and in particular the risk of atrial fibrillation (AF), related to anti-osteoporotic drug use is inconclusive. The objective of this study was to evaluate the association between the use of bisphosphonates (BPs), strontium ranelate (SR), and other anti-osteoporosis drugs and the risk of AF and CCV events in a large cohort of patients affected by CCV diseases. Methods: Based on a cohort of patients aged 65 years and over, discharged from the hospitals of five large Italian areas after a CCV event between 2008 and 2011, two nested case-control studies were conducted. Cases were patients with a subsequent hospital admission for AF or CCV; four controls for each case were randomly selected and matched by age group, sex and follow-up time. A total of three exposure measures were tested: ever use, adherence and recency of use. In the conditional logistic regression models, patients not treated with any anti-osteoporotic medication were considered as the reference category. Results: The initial cohort accounted for 657,246 patients. Neither BPs nor SR use was associated with an increased risk of AF regardless of the adherence and recency of use. Overall BP and SR use was associated with a slightly increased risk of CCV; however, results reversed when considering higher adherence: odds ratio (OR) 0.81, 95% confidence interval (CI) 0.71-0.92 for BPs and OR 0.71, 95% CI 0.52-0.97 for SR. Conclusions: BPs do not increase cardiovascular risk and can be prescribed to elderly patients for osteoporosis treatment. However, patients with pre-existing cerebrovascular/cardiovascular conditions should be carefully monitored.
- Published
- 2019
49. A systematic review of case-identification algorithms based on italian healthcare administrative databases for three relevant diseases of the cardiovascular system: Acute myocardial infarction, ischemic heart disease, and stroke
- Author
-
Hyeraci, G, Spini, A, Roberto, G, Gini, R, Bartolini, C, Lucenteforte, E, Corrao, G, Rea, F, Hyeraci, Giulia, Spini, Andrea, Roberto, Giuseppe, Gini, Rosa, Bartolini, Claudia, Lucenteforte, Ersilia, Corrao, Giovanni, Rea, Federico, Hyeraci, G, Spini, A, Roberto, G, Gini, R, Bartolini, C, Lucenteforte, E, Corrao, G, Rea, F, Hyeraci, Giulia, Spini, Andrea, Roberto, Giuseppe, Gini, Rosa, Bartolini, Claudia, Lucenteforte, Ersilia, Corrao, Giovanni, and Rea, Federico
- Abstract
BACKGROUND: acute myocardial infarction (AMI), ischemic heart diseases (IHDs) and stroke are serious cardiovascular diseases (CVDs) which may lead to hospitalizations, require periodical medical monitoring and life-long drugs use, thus having a high impact on public health and Healthcare Service expenditure. In this contest, Italian Healthcare Administrative Databases (HADs), which routinely collect patient-level information on healthcare services reimbursed by the National Healthcare service, are increasingly used for identification of these CVDs. ObjectiveS: to identify and describe all AMI, IHDs and stroke case-identification algorithms by means of Italian HADs, through the review of papers published in the past 10 years. Methods: this study is part of a project that systematically reviewed case-identification algorithms for 18 acute and chronic conditions by means of HADs in Italy. PubMed was searched for original articles, published between 2007 and 2017, in Italian or English. The search string consisted of a combination of free text and MeSH terms with a common part that focused on HADs and a disease-specific part. All identified papers were screened by two independent reviewers. Pertinent papers were classified according to the objective for which the algorithm had been used, and only articles that used algorithms for primary objectives (I disease occurrence; II population/cohort selection; III outcome identification) were considered for algorithm extraction. The HADs used (hospital discharge records, drug prescriptions, etc.), ICD-9 and ICD-10 codes, ATC classification of drugs, follow-back periods, and age ranges applied by the algorithms have been reported. Further information on specific objective(s), accuracy measures, sensitivity analyses and the contribution of each HAD, have also been recorded. Results: the search strategy has led to the identification of 611 papers for AMI,801 for IHDs and 791 for stroke. Among these,45,12 and 31 papers for AMI, IHD
- Published
- 2019
50. The Role of European Healthcare Databases for Post-Marketing Drug Effectiveness, Safety and Value Evaluation: Where Does Italy Stand?
- Author
-
Trifirò, G, Gini, R, Barone-Adesi, F, Beghi, E, Cantarutti, A, Capuano, A, Carnovale, C, Clavenna, A, Dellagiovanna, M, Ferrajolo, C, Franchi, M, Ingrasciotta, Y, Kirchmayer, U, Lapi, F, Leone, R, Leoni, O, Lucenteforte, E, Moretti, U, Mugelli, A, Naldi, L, Poluzzi, E, Rafaniello, C, Rea, F, Sultana, J, Tettamanti, M, Traversa, G, Vannacci, A, Mantovani, L, Corrao, G, Trifirò, Gianluca, Gini, Rosa, Barone-Adesi, Francesco, Beghi, Ettore, Cantarutti, Anna, Capuano, Annalisa, Carnovale, Carla, Clavenna, Antonio, Dellagiovanna, Mirosa, Ferrajolo, Carmen, Franchi, Matteo, Ingrasciotta, Ylenia, Kirchmayer, Ursula, Lapi, Francesco, Leone, Roberto, Leoni, Olivia, Lucenteforte, Ersilia, Moretti, Ugo, Mugelli, Alessandro, Naldi, Luigi, Poluzzi, Elisabetta, Rafaniello, Concita, Rea, Federico, Sultana, Janet, Tettamanti, Mauro, Traversa, Giuseppe, Vannacci, Alfredo, Mantovani, Lorenzo, Corrao, Giovanni, Trifirò, G, Gini, R, Barone-Adesi, F, Beghi, E, Cantarutti, A, Capuano, A, Carnovale, C, Clavenna, A, Dellagiovanna, M, Ferrajolo, C, Franchi, M, Ingrasciotta, Y, Kirchmayer, U, Lapi, F, Leone, R, Leoni, O, Lucenteforte, E, Moretti, U, Mugelli, A, Naldi, L, Poluzzi, E, Rafaniello, C, Rea, F, Sultana, J, Tettamanti, M, Traversa, G, Vannacci, A, Mantovani, L, Corrao, G, Trifirò, Gianluca, Gini, Rosa, Barone-Adesi, Francesco, Beghi, Ettore, Cantarutti, Anna, Capuano, Annalisa, Carnovale, Carla, Clavenna, Antonio, Dellagiovanna, Mirosa, Ferrajolo, Carmen, Franchi, Matteo, Ingrasciotta, Ylenia, Kirchmayer, Ursula, Lapi, Francesco, Leone, Roberto, Leoni, Olivia, Lucenteforte, Ersilia, Moretti, Ugo, Mugelli, Alessandro, Naldi, Luigi, Poluzzi, Elisabetta, Rafaniello, Concita, Rea, Federico, Sultana, Janet, Tettamanti, Mauro, Traversa, Giuseppe, Vannacci, Alfredo, Mantovani, Lorenzo, and Corrao, Giovanni
- Abstract
Enormous progress has been made globally in the use of evidence derived from patients’ clinical information as they access their routine medical care. The value of real-world data lies in their complementary nature compared with data from randomised controlled trials: less detailed information on drug efficacy but longer observational periods and larger, more heterogeneous study populations reflecting clinical practice because individuals are included who would not usually be recruited in trials. Real-world data can be collected in various types of electronic sources, such as electronic health records, claims databases and drug or disease registries. These data sources vary in nature from country to country, according to national healthcare system structures and national policies. In Italy, a growing number of healthcare databases have been used to evaluate post-marketing drug utilisation and safety in the last two decades. The aim of this narrative review is to describe the available Italian sources of real-world data and their contribution to generating post-marketing evidence on drug use and safety. We also discuss the strengths and limitations of the most commonly used Italian healthcare databases in addressing various research questions concerning drug utilisation, comparative effectiveness and safety studies, as well as health technology assessment and other areas
- Published
- 2019
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.